Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study
Open Access
- 24 October 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (13), 982-992
- https://doi.org/10.1093/eurheartj/ehs344
Abstract
Statins reduce LDL cholesterol (LDL-C) and the risk of vascular events, but it remains uncertain whether there is clinically relevant genetic variation in their efficacy. This study of 18 705 individuals aims to identify genetic variants related to the lipid response to simvastatin and assess their impact on vascular risk response. A genome-wide study of the LDL-C and apolipoprotein B (ApoB) response to 40 mg simvastatin daily was performed in 3895 participants in the Heart Protection Study, and the nine strongest associations were tested in 14 810 additional participants. Selected candidate genes were also tested in up to 18 705 individuals. There was 90% power to detect differences of 2.5% in LDL-C response (e.g. 42.5 vs. 40% reduction) in the genome-wide study and of 1% in the candidate gene study. None of the associations from the genome-wide study was replicated, and nor were significant associations found for 26 of 36 candidates tested. Novel lipid response associations with variants in LPA, CELSR2/PSRC1/SORT1, and ABCC2 were found, as well as confirmatory evidence for published associations in LPA, APOE, and SLCO1B1. The largest and most significant effects were with LPA and APOE, but were only 2–3% per allele. Reductions in the risk of major vascular events during 5 years of statin therapy among 18 705 high-risk patients did not differ significantly across genotypes associated with the lipid response. Common genetic variants do not appear to alter the lipid response to statin therapy by more than a few per cent, and there were similar large reductions in vascular risk with simvastatin irrespective of genotypes associated with the lipid response to simvastatin. Consequently, their value for informing clinical decisions related to maximizing statin efficacy appears to be limited.Keywords
This publication has 31 references indexed in Scilit:
- Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)Journal of Lipid Research, 2012
- Large-scale association analysis identifies 13 new susceptibility loci for coronary artery diseaseNature Genetics, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Biological, clinical and population relevance of 95 loci for blood lipidsNature, 2010
- Genome-Wide Association of Lipid-Lowering Response to Statins in Combined Study PopulationsPLOS ONE, 2010
- Comprehensive Whole-Genome and Candidate Gene Analysis for Response to Statin Therapy in the Treating to New Targets (TNT) CohortCirculation: Cardiovascular Genetics, 2009
- A Gene-Centric Approach to Elucidating Cardiovascular RiskCirculation: Cardiovascular Genetics, 2009
- SLCO1B1 variants and statin-induced myopathy - A genomewide studyThe New England Journal of Medicine, 2008
- Clinical implications of pharmacogenomics of statin treatmentThe Pharmacogenomics Journal, 2006
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study)The American Journal of Cardiology, 1998